BioCentury
ARTICLE | Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

October 31, 2019 8:56 PM UTC

As Roivant cements its deal for Dainippon to acquire five of its “vants” for $3 billion, the biotech revealed the identity of the deal’s fifth subsidiary, which will develop gene therapies for cystic fibrosis.

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) will house the five vertically-focused units in a new company, which Myrtle Potter will lead as CEO. She joined Roivant Sciences Ltd. as its vant operating chair in 2018 after more than a decade as an independent consultant; she was EVP and COO of Genentech Inc. in 2000-04...